Cambrex adds new development and analytical equipment in Italy

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/suprunvitaly)
(Image: Getty/suprunvitaly)

Related tags: Active ingredient

Cambrex Corporation has announced a new investment in its research and development (R&D) and manufacturing capabilities at its site in Paullo, Milan, Italy.

According to the company, it has installed development and analytical equipment to support the development of highly potent APIs (HPAPIs), including a new 2,800-liter hydrogenator and 1,500mm diameter centrifuge.

Equipment installation and validation with be concluded by the end of 2017.

The small molecule and generic Active Pharmaceutical Ingredients (APIs) manufacturer opened the pilot plant in October 2016 at which time it said further upgrades would follow in order to support the production of Class 3/4 high potency products.

The cGMP plant can produce batch sizes from 1kg to 15kg.

Cambrex also invested $24m​ in a new Charles City, Iowa plant earlier this year. The facility is expected to be open in 2019.

The company’s High Point, NC-based facility was also expanded​ to include a new $3.2m, 11,000 square foot analytical laboratory in August. 

Related news

Show more

Related products

show more


Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us


View more